Hims & Hers Shares Fall After Missing Revenue and Subscriber Expectations
Hims & Hers stock drops after missing revenue and subscriber expectations. Q3 revenue rose 49% to $890M, but margins compressed and guidance tightened.
Hims & Hers stock drops after missing revenue and subscriber expectations. Q3 revenue rose 49% to $890M, but margins compressed and guidance tightened.
Lilly partners with Hims & Hers so patients can access Zepbound ($299/mo) and Foundayo ($149/mo) at self-pay prices on the telehealth platform.
Hims & Hers shares rose after HHS said it will temporarily allow compounding pharmacies to produce six popular peptides, including BPC-157, while regulators review formal approval.
Hims launches nationwide men’s care in Australia after buying Eucalyptus.
Visa flags Hims for high dispute rates on $39-to-$149 weight-loss memberships. Company faces fees, scrutiny, and must lower rate for 3 months.
Despite beating estimates and raising full-year outlook, HIMS stock dropped after investors focused on the bigger-than-expected loss and collapsing margins.